Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Neuropharmacology. 2023 Mar 6;230:109489. doi: 10.1016/j.neuropharm.2023.109489

Fig. 2.

Fig. 2.

Binding assays with the 5-HT2AR agonist [3H]LSD, antagonist [3H]M100907 and inverse agonist [18F]altanserin show increased, unaffected and decreased 5-HT2AR densities, respectively, in frontal cortex samples of schizophrenia subjects. These divergent receptor density values may be explained by their preferences in terms of affinity for the active vs inactive conformations of the 5-HT2AR.